Carregant...
EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1...
Guardat en:
| Publicat a: | Respir Med Case Rep |
|---|---|
| Autors principals: | , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5524632/ https://ncbi.nlm.nih.gov/pubmed/28761805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.05.010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|